Methylxanthines enhance the effects of cocoa flavanols on cardiovascular function: randomized, double-masked controlled studies

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open Access


It is advisable to refer to the publisher’s version if you intend to cite from the work.

To link to this article DOI: http://dx.doi.org/10.3945/ajcn.116.140046

Publisher: American Society for Nutrition

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in
the End User Agreement.

www.reading.ac.uk/centaur

CentAUR
Central Archive at the University of Reading
Reading’s research outputs online
Methylxanthines enhance the effects of cocoa flavanols on cardiovascular function: randomized, double-masked controlled studies

Roberto Sansone,1 Javier I Ottaviani,2 Ana Rodriguez-Mateos,2,4 Yvonne Heinen,2 Dorina Noske,2 Jeremy P Spencer,5 Alan Crozier,6 Marc W Merx,2 Malte Kelm,2 Hagen Schroeter,3 and Christian Heiss2*

2Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany; 3Division of Diabetes and Nutritional Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom; 4Molecular Nutrition Group, School of Chemistry, Food and Pharmacy, University of Reading, Reading, United Kingdom; and 5Department of Nutrition, University of California Davis, Davis, CA

ABSTRACT

Background: Cocoa flavanol intake, especially that of (−)-epicatechin, has been linked to beneficial effects on human cardiovascular function. However, cocoa also contains the methylxanthines theobromine and caffeine, which may also affect vascular function.

Objective: We sought to determine whether an interaction between cocoa flavanols and methylxanthines exists that influences cocoa flavanol–dependent vascular effects.

Design: Test drinks that contained various amounts of cocoa flavanols (0–820 mg) and methylxanthines (0–220 mg), either together or individually, were consumed by healthy volunteers (n = 47) in 4 different clinical studies—3 with a randomized, double-masked crossover design and 1 with 4 parallel crossover studies. Vascular status was assessed by measuring flow-mediated vasodilation (FMD), brachial pulse wave velocity (bPWV), circulating angiogenic cells (CACs), and blood pressure before and 2 h after the ingestion of test drinks.

Results: Although cocoa flavanol intake increased FMD 2 h after intake, the consumption of cocoa flavanols with methylxanthines resulted in a greater enhancement of FMD. Methylxanthine intake alone did not result in statistically significant changes in FMD. Cocoa flavanol ingestion alone decreased BP and diastolic blood pressure and increased CACs. Each of these changes was more pronounced when cocoa flavanols and methylxanthines were ingested together. It is important to note that the area under the curve of the plasma concentration of (−)-epicatechin metabolites over time was higher after the co-ingestion of cocoa flavanols and methylxanthines than after the intake of cocoa flavanols alone. Similar results were obtained when pure (−)-epicatechin and the methylxanthines theobromine and caffeine were consumed together.

Conclusion: A substantial interaction between cocoa flavanols and methylxanthines exists at the level of absorption, in which the methylxanthines mediate an increased plasma concentration of (−)-epicatechin metabolites that coincides with enhanced vascular effects commonly ascribed to cocoa flavanol intake. This trial was registered at clinicaltrials.gov as NCT02149238. Am J Clin Nutr 2017;105:352–60.

Keywords: cocoa flavanols, methylxanthines, cardiovascular function, interaction, absorption
amounts of other methylxanthines can also be found in these food products (11).

A rich data set exists that describes methylxanthine bioactivity in humans, and several biological effects have been well described (12, 13). In addition to the more commonly referenced effects on the central nervous system, methylxanthines, particularly caffeine, have been demonstrated to directly modulate vascular functions, including BP, arterial stiffness, and endothelial function (14–16). In addition, co-ingestion can potentially affect the absorption and plasma concentration of other compounds. For instance, caffeine potentiates the analgesic and anti-inflammatory actions of aspirin and increases absorption and plasma concentration without influencing the volume of distribution and clearance (17, 18). Thus, based on the presence of both flavanols and methylxanthines in cocoa, we investigated the potential role of methylxanthines as modulators of the cardiovascular effects of CFs in humans. We hypothesized that an interaction between CFs and methylxanthines exists that modulates CF-dependent vascular effects. To investigate this hypothesis, we performed 4 studies, each of which aimed to answer a specific question.

**METHODS**

**Subjects**

Subjects for this study (NCT02149238) were recruited between 2011 February and 2014 December and consisted of healthy young men aged 25–30 y. All subjects with symptoms of subjects were randomly assigned to the 4 parallel arms. In each arm, volunteers were given test drinks that were consumed during the 10 (arms 1 and 2) or 8 (arms 3 and 4) different study visits (crossover). The test drinks consisted of increasing amounts of CFs (0, 102, 205, 410, and 820 mg) (arm 1); increasing amounts of CFs (0, 102, 205, 410, and 820 mg) in the presence of 122 mg methylxanthines (arm 2); increasing amounts of methylxanthines (0, 61, 122, and 244 mg) (arm 3); and increasing amounts of methylxanthines (0, 61, 122, and 244 mg) in the presence of 820 mg CFs (arm 4). Volunteers consumed the test drinks on the study days, and FMD (first endpoint) measurements were taken before (0 h) and 2 h after ingestion.

**Study design**

Study protocol 1 was designed as the main proof-of-concept study and aimed at assessing potential interactions of CFs and methylxanthines with regard to the modulation of cardiovascular function, including flow-mediated vasodilation (FMD) (first endpoint), arterial stiffness, BP, and CACs (second endpoint). To accomplish this, an acute 3-arm, single-center, randomized, double-masked crossover study (n = 12) was carried out at Heinrich-Heine University Düsseldorf (HHUD). The 3 test drinks consumed by the volunteers provided CFs at 820 mg CFs, including flavanols and methylxanthines at 125 mg CFs per 75-kg BW either together or individually. Table 1 shows the composition of the base powder used to reconstitute the drinks. The total amount of CFs represents the sum of monomers and oligomers (procyanidins) with a degree of polymerization from 1 to 10. The predominant monomer in the test drinks was (−)-epicatechin; the (−)-epicatechin content of the test drinks was ~112 mg/75 kg BW. All intake amounts were given on a per 75-kg BW basis (for clarity, applied amounts are only presented as milligrams henceforth). On the 3 study days, which were separated by a 1-wk washout, volunteers consumed the test drinks, and cardiovascular functions were assessed before (0 h) and 2 h (the time of peak FMD effects) after intake. Randomization and allocation to the 3 interventions were based on an electronic treatment plan generated by a GraphPad web application (www.graphpad.com; GraphPad Software Inc.).

To study the effect of methylxanthines consumed with CFs at different intake amounts. To accomplish this, a single-center (HHUD), randomized, double-masked 4-arm study (n = 24; n = 6/group) was conducted. Subjects were randomly assigned to the 4 parallel arms. In each arm, volunteers were given test drinks that were consumed during the 10 (arms 1 and 2) or 8 (arms 3 and 4) different study visits (crossover). The test drinks consisted of increasing amounts of CFs (0, 102, 205, 410, and 820 mg) (arm 1); increasing amounts of CFs (0, 102, 205, 410, and 820 mg) in the presence of 122 mg methylxanthines (arm 2); increasing amounts of methylxanthines (0, 61, 122, and 244 mg) (arm 3); and increasing amounts of methylxanthines (0, 61, 122, and 244 mg) in the presence of 820 mg CFs (arm 4). Volunteers consumed the test drinks on the study days, and FMD (first endpoint) measurements were taken before (0 h) and 2 h after ingestion.

Study protocol 3 investigated how methylxanthines might modulate the plasma concentration and urinary excretion of the structurally related (−)-epicatechin metabolites (SREMs) and the temporal association with FMD increases. This study was conducted at HHUD and followed a randomized, double-masked, 2-arm crossover design (n = 5). Volunteers were asked to consume the test drinks on the study day, and blood and 0- to 24-h urine samples were collected following previously described procedures (19). FMD (first endpoint) and blood sample measurements were taken to determine SREMs (second endpoint) and were performed before (0 h) and 1, 2, 3, 4, and 5 h after the ingestion of the test drink. The 2 test drinks consumed by the volunteers contained 820 mg CFs, including 112 mg (−)-epicatechin, in either the absence or presence of 122 mg methylxanthines comprising 111 mg theobromine and 11 mg caffeine (Table 1).

**Table 1**

<table>
<thead>
<tr>
<th>Serving size, g/75 kg BW</th>
<th>CF + MX</th>
<th>CF</th>
<th>MX</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.2</td>
<td>13.2</td>
<td>13.2</td>
<td></td>
</tr>
<tr>
<td>111.8</td>
<td>112.8</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>3.2</td>
<td>3.8</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>11.6</td>
<td>35</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>820</td>
<td>820</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>111.0</td>
<td>1.6</td>
<td>112.8</td>
<td></td>
</tr>
<tr>
<td>11.4</td>
<td>1.2</td>
<td>10.2</td>
<td></td>
</tr>
<tr>
<td>122.4</td>
<td>2.8</td>
<td>123.0</td>
<td></td>
</tr>
<tr>
<td>35.4</td>
<td>34</td>
<td>37.4</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>5.8</td>
<td>5.4</td>
<td>5.8</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>78</td>
<td>70</td>
<td>82</td>
<td></td>
</tr>
</tbody>
</table>

1 BW, body weight; CF, cocoa flavanol; MX, methylxanthine; ND, below limit of detection.
Study protocol 4 assessed the effects of pure theobromine and caffeine consumed simultaneously with (−)-epicatechin on plasma concentrations (first endpoints) and the urinary excretion of SREMs (second endpoint). To accomplish this, a single-center, randomized, double-masked crossover study \((n = 6)\) was carried out at the University of California Davis, during which volunteers consumed 75 mg (−)-epicatechin either with or without 400 mg theobromine and 26 mg caffeine on 2 different days. On the study day, blood samples were drawn before (0 h) and 1, 2, and 4 h after the consumption of test drinks, and 0- to 24-h urine samples were collected following previously described procedures \(\text{(19)}\).

In all studies, volunteers were asked to follow a low-flavanol diet and to refrain from consuming alcohol, coffee, or other beverages that contain caffeine on the day before and during the study visits. Volunteers were also asked to fast for 12 h before each study day (water ad libitum). Study visits were scheduled ≥1 wk apart to avoid potential carryover effects. The study protocols were approved by the HHUD ethics committee and the University of California Davis institutional review board; all volunteers gave written informed consent.

**Test drinks containing CFs and methylxanthines**

Specifically designed test drinks that contained CFs and methylxanthines either together or individually were used in all studies. The amount of test drinks consumed was standardized on a per 75-kg BW basis, and regardless of the amount of CFs and methylxanthines, all test drinks used in the same study contained similar macro- and micronutrients, as well as very similar orosensory and physicochemical characteristics.

The test drinks used in study protocols 1–3 consisted of fruit-flavored nondairy drinks that contained CFs and the methylxanthines theobromine and caffeine either individually or together (Table 1). These test drinks were prepared for a 75-kg subject by reconstituting 13.2 g of a drink powder with 500 mL water to achieve a content of 820 mg CFs and/or 122 mg methylxanthines. Other intake amounts were achieved with the use of more or less of the identical drink powders in 500 mL water (e.g., 6.6 g to achieve 410 mg CFs). The source of CFs and methylxanthines in the test drinks that contained both groups of compounds simultaneously consisted of a standardized cocoa extract manufactured with the use of the Cocoapro process (Mars Inc.).

To prepare the drinks provided in study protocol 4, we used food-grade (−)-epicatechin isolated from cocoa (Mars Inc.); food-grade theobromine (AHD International LLC) and caffeine (Perrigo) were added to milk (1% fat) as a vehicle for delivering these compounds. The final composition of the test drinks was as follows: 75 mg (−)-epicatechin, 400 mg theobromine, and 26 mg caffeine dissolved in 375 g milk and 75 mg (−)-epicatechin dissolved in 375 g milk.

**FMD assessment**

FMD was measured as previously described \(\text{(7)}\). Briefly, the diameter and flow velocity of the brachial artery was measured with the use of a Vivid I 10-MHz transducer (General Electric) and automatic edge-detection software (Brachial Analyzer version 5; Medical Imaging Applications) that yielded SDs of mean differences between repeated measurements of <1%. The brachial artery diameter was measured 2 cm proximal to the elbow. Reactive hyperemia was induced by 5 min of distal lower-arm occlusion with a sphygmonanometric cuff inflated to 250 mm Hg. After cuff deflation (20, 40, 60, and 80 s), the diameter was assessed, and the FMD was calculated as the maximal relative diameter gain relative to the baseline. Sublingual nitroglycerin (0.4 mg) was administered, and endothelium-independent nitroglycerin-mediated dilation was assessed at 4 min. The FMD was expressed as \(\text{FMD} = \left(\text{diameter}_{\text{max}} - \text{diameter}_{\text{baseline}}\right)/\text{diameter}_{\text{baseline}} \times 100\).

FMD was defined as the primary outcome (studies 1–3); thus, power calculations were based on FMD. The intra- and interindividual variability for FMD measurements established in our laboratory are 0.9% (SDs of differences between repeated FMD measurements in 20 healthy subjects) \(\text{(C Heiss, unpublished results, 2015)}\) and 1% (SDs within a group of healthy subjects), respectively. Therefore, a crossover study with 12, 6, or 5 subjects receiving treatments on 2 separate days would provide sufficient power to detect an absolute change in FMD of 0.8%, 1.3%, or 1.5% \(\left(2\text{-}\alpha = 0.05; \text{power} = 0.80\right)\). For parallel independent group comparisons in study 2, 6 subjects receiving different treatments would provide sufficient power to detect absolute differences in FMD mean values of 1.8% \(\left(2\text{-}\alpha = 0.05; \text{power} = 0.80\right)\).

**Arterial stiffness assessment**

Arterial stiffness was determined by assessing the brachial PWV (bPWV) before and 2 h after administering the test drinks in study 1. The bPWV was calculated by dividing the distance between the suprasternal notch to the cubital fossa by the pulse transit time. The pulse transit time from the heart to the brachial artery was calculated as the time delay between the R wave on an electrocardiogram and the beginning of the systolic Doppler flow velocity taken during brachial artery ultrasound exams. The distance between the suprasternal notch via the shoulder to the cubital fossa was determined with measuring tape.

**BP measurements**

Office BP was measured in study 1 before and 2 h after administering the test drinks in study 1 with the use of an automated clinical digital sphygmomanometer (Dynamap) at the upper left arm in the supine position after 10 min of rest in a quiet room with the arm at heart level before blood was drawn and FMD was measured. We took 3 measurements and discarded the first and calculated the mean values for the second and third for further analysis.

**CAC quantification with the use of flow cytometry**

CACs were isolated and quantitated with the use of flow cytometry as described previously \(\text{(20)}\). Briefly, blood was drawn in study 1 in heparinized vacutainer tubes before and 2 h after the ingestion of the 3 drinks, and the number of CACs in whole blood was measured as CD34/kinase insert domain receptor (KDR) double-positive cells with the use of flow cytometry. Staining was performed after washing with phosphate-buffered saline (PBS) and Fc receptor blocking (Ig: 1 mg/mL; Zymed). Phycoerythrin (CD34) and allophycocyanin (KDR)-conjugated anti-human mouse antibodies (Pharmingen) or isotype controls were incubated with a 100-μL \(\left(10^5\text{-}\text{mL}\right)\) cell suspension with the use
of a fluorescence-activated cell-sorting buffer (1% bovine serum albumin/PBS) for 20 min. After lysing red blood cells and washing with the fluorescence-activated cell-sorting buffer twice, cells were fixed with 1% formaldehyde/PBS and stored at 4°C until analysis; 100,000 events were collected in the lymphocyte and monocyte gates (FACSCanto; Becton Dickinson).

Quantification of (−)-epicatechin metabolites in plasma and urine

The quantification of SREMs corresponding to the sum of sulfated, glucuronidated, and O-methylated (−)-epicatechin metabolites was assessed in plasma and urine with the use of HPLC. Samples were analyzed with the use of a reversed-phase chromatograph equipped with a 4.6-mm Luna C18 column (3-μm particle size; Phenomenex) and a Hewlett-Packard 1200-series chromatograph equipped with a fluorescence detector operating at 276 nm (excitation) and 316 nm (emission) as described previously (19). Authentic reference SREMs were provided by Mars Inc.

As published previously (21), the intraindividual variability in the peak plasma concentration (Cmax) and 0 to 6-h AUC (AUC0–6h) of total SREMs was 16% and 17%, respectively. The interindividual variability in the AUC0–6h and Cmax of total SREMs was 38% and 39%, respectively. Plasma concentrations of SREMs were defined as the primary outcome of study 4; therefore, power calculations were based on SREMs. The intraindividual variability for the Cmax of total SREMs established in our laboratory was 200 nmol/L (SDs of differences between repeated SREM measurements after acute consumption of identical drinks containing 10.3 mg/kg BW of CFs in 7 healthy subjects) (21). Therefore, our crossover studies with 6 subjects who received treatments on 2 separate days provided sufficient power to detect an absolute change in SREMs of 285 nmol/L (2-sided α = 0.05; power = 0.80).

Statistical analyses

Results are expressed as means ± SDs. Groups were compared with the use of 2-factor repeated-measures ANOVA, and, if significant, a consecutive Bonferroni post hoc test was performed. The ANOVA in studies 1, 3, and 4 had the 2 within-subject factors (time and treatment). In study 2, we compared the changes in FMD at 2 h with the baseline between treatments. We performed 2 separate mixed-model 2-factor ANOVAs with 1 within-subject factor (methylxanthines: 0, 61, 122, and 244 mg; CFs: 0, 102, 205, 410, and 820 mg) and 1 between-subject factor (methylxanthines: 0 and 122 mg; CFs: 0 and 820 mg). Linear relations between continuous variables were expressed as Pearson’s r. P ≤ 0.05 was considered statistically significant. Statistical analyses were performed with the use of SPSS version 19 (IBM). Intake amount–response relations were analyzed with the use of a nonlinear curve fit with Graph Pad Prism 6, and intake amounts of zero were arbitrarily set to 1.

RESULTS

Baseline characteristics of study groups

The overall study population consisted of 47 young and healthy men. Figure 1 shows the Consolidated Standards of Reporting Trials study flow diagram, distribution of subjects to studies, and individual study protocols. The characteristics of the study population are summarized in Table 2. No significant differences were observed between the volunteers in the individual studies, and all drinks were well tolerated. No adverse effects or side effects were observed in any of the studies.

Methylxanthines increase the effects of CFs on vascular biomarkers (study 1)

Study protocol 1 investigated whether the co-administration of methylxanthines and CFs would modulate CF-related effects on established biomarkers of vascular function, including FMD, BP, PWV, and CACs. The results showed that the ingestion of both test drinks containing CFs resulted in a significant increase in FMD 2 h after intake compared with the baseline (Figure 2A). Furthermore, the increase in FMD after the intake of the test drink containing both CFs and methylxanthines was greater than after the intake of the drink containing only CFs (1.7% ± 0.6% compared with 0.8% ± 0.3%, respectively; P < 0.05). No changes in FMD were observed with the intake of the test drink containing methylxanthines only (0.1% ± 0.5%). No statistically significant difference in nitroglycerin-mediated dilation at the end of each study visit was observed (after CF intake: 14.6% ± 1.0%.

FIGURE 1 Study flow (CONSORT diagram) (A) and schematics of study protocols (B). BL, baseline; BW, body weight; CF, cocoa flavanol; CONSORT, Consolidated Standards of Reporting Trials; HHUD, Heinrich-Heine University Düsseldorf; MX, methylxanthine; UCD, University of California Davis.

Downloaded from https://academic.oup.com/ajcn/article-abstract/105/2/352/4633941 by University of Reading user on 22 November 2018
CF and methylxanthine intake: 14.6% ± 2.5%; methylxanthine intake: 14.2% ± 1.0%; \(P = 0.421\), demonstrating that none of the test drinks changed the endothelium-independent vasodilation response.

In addition to FMD, bPWV, BP, and the number of CACs were assessed. Only the ingestion of the test drink containing CFs resulted in significant changes in CD34+/KDR+ CACs (5 ± 4-fold increase; \(P < 0.001\)) as well as bPWV (−0.26 ± 0.14 m/s; \(P = 0.011\)), with no effect on diastolic BP (−2 ± 6 mm Hg; Figure 2B–D). The consumption of the test drink containing CFs and methylxanthines together also resulted in positive changes in CD34+/KDR+ CACs (12 ± 4-fold; \(P < 0.001\)) and decreased bPWV (−0.46 ± 0.22 m/s; \(P = 0.011\)) and diastolic BP (−6 ± 4 mm Hg; \(P = 0.011\)). Similar to the findings on FMD, however, the magnitude of the changes on CD34+/KDR+ CACs, bPWV, and diastolic BP after the intake of CFs and methylxanthines simultaneously were greater than after the intake of only CFs. No significant changes in the vascular parameters were observed after the intake of the test drink containing only methylxanthines. Systolic BP and heart rate were not significantly affected by the ingestion of any of the test drinks. In summary, the intake of CFs acutely improved multiple functional markers of vascular health, and, notably, the co-ingestions of CFs with methylxanthines enhanced the effect of CFs on the vascular function biomarkers investigated, namely FMD, CACs, bPWV, and diastolic BP.

**Intake amount dependence of interaction between methylxanthines and CFs (study 2)**

Study protocol 2 investigated changes in FMD after the intake of test drinks containing a range of intake amounts of CFs and methylxanthines. Volunteers who consumed increasing amounts of CFs (n = 6) showed a significant intake amount–dependent increase in FMD 2 h after the intake of >105 mg compared with the baseline (Figure 3A). This increase in FMD depended on the amount of CFs consumed, with a maximal FMD increase (\(\Delta\text{FMD}_{\text{max}}\)) of 1.4% (95% CI: 1.2%, 1.7%) after 820 mg and an intake amount to achieve a half-maximal increase (\(ED_{50}\)) of 199 mg (95% CI: 150, 264 mg; \(R^2 = 0.87\)).

When volunteers consumed test drinks with increasing amounts of CFs in conjunction with 122 mg methylxanthines (n = 6), there was a CF intake–dependent increase in FMD 2 h after intake, with a \(\Delta\text{FMD}_{\text{max}}\) of 2.5% (95% CI: 1.9%, 3.1%) after the ingestion of 820 mg CFs and an \(ED_{50}\) of 226 mg (95% CI: 152, 335 mg;
The effects of theobromine and caffeine on plasma SREM concentrations after the intake of (−)-epicatechin (study 4)

Results similar to study 3 were obtained when applying study protocol 4, in the context of which CFs and methylxanthines were provided in a cocoa-free formulation that emulated the composition of naturally occurring cocoa with respect to its content of (−)-epicatechin, theobromine, and caffeine. The consumption of the test drinks containing either (−)-epicatechin alone and a combination of (−)-epicatechin and theobromine and caffeine significantly increased the SREM Cmax, with maximal values 2 h after intake (Figure 4C). Consistent with data from study protocol 3, a higher SREM Cmax was detected after the consumption of the test drink containing theobromine and caffeine and (−)-epicatechin than with the Cmax attained after the intake of the test drink containing only (−)-epicatechin (P < 0.005). The plasma AUCs of SREM concentrations compared with the time for ≤4 h (AUC0–4 h) after the intake of the test drink containing (−)-epicatechin and theobromine and caffeine was 22% ± 5% higher than the AUC0–4 h after the intake of the drink containing (−)-epicatechin only (1.43 ± 0.22 compared with 1.76 ± 0.40 μmol/h; P = 0.014). No differences in the amount of SREMs excreted in the 0- to 24-h urine samples were observed after the intake of either drink [10.8 ± 2.1 compared with 11.1 ± 2.1 μmol; P > 0.05 for the test drink containing (−)-epicatechin and theobromine and caffeine compared with (−)-epicatechin only].

DISCUSSION

The intake of test drinks containing CFs either with or without methylxanthines resulted in acute improvements of established functional cardiovascular biomarkers in healthy adults, namely FMD, CAC, PWV, and diastolic BP. These findings are in agreement with previous studies that have reported beneficial vascular effects after the intake of CFs or foods containing flavonols (7, 8). In contrast, the intake of methylxanthines alone did not mediate acute changes in the biomarkers assessed herein. Although the consumption of methylxanthines has been reported to modulate certain vascular parameters (15, 22), it is plausible that the amounts of methylxanthines administered herein or the...
matrix in which they were consumed were not conducive for mediating the effects on the observed parameters. When CFs and methylxanthines were ingested simultaneously, as occurs normally in the context of cocoa that contains CFs, changes over the baseline in FMD, CACs, and PWV of 47%, 42%, and 57%, respectively, were observed, indicating the existence of a synergistic mode of action. The results of study 2 confirmed these findings and further proved that this synergistic effect depended on the amount of CFs and methylxanthines consumed. An important consequence of this synergism is that it may explain to a certain degree the variability in the magnitude of effects observed in different studies with test materials containing varying amounts of CFs and methylxanthines (23). In this context, we and others have shown that the intake of pure (−)-epicatechin can acutely improve endothelial function after the consumption of 1–2 mg/kg BW (5, 10). It is important to note that the effect size of (−)-epicatechin intake observed herein was smaller than an earlier study (5) in which the test drink contained both CFs and methylxanthines.

A recent study on the effects of (−)-epicatechin intake (24) did not detect statistically significant long-term changes in FMD. It may be that investigations that use a purified dietary constituent do not fully mimic the effects or effect sizes observed when the same constituent is consumed in its native food or food matrix. Our data demonstrate that the effect of (−)-epicatechin intake-related changes in vascular function is greater when the flavanol is consumed with methylxanthine, similar to the consumption of (−)-epicatechin as part of certain teas or cocoas.

These data indicate that methylxanthines, when consumed together with CFs, lead to significantly higher concentrations of plasma SREMs without affecting excretion. These findings confirm previous results in rats that suggested that theobromine intake increases the absorption of (−)-epicatechin (12, 25). A similar pattern is observed when aspirin is consumed together with caffeine (18). Potential mechanisms by which methylxanthines may increase (−)-epicatechin (or aspirin) absorption are unknown but may include specific effects on gastrointestinal physiology (e.g., motility and/or secretion, blood flow, gastric pH) or even the modulation of transporters that regulate the efflux of SREMs in the gut. The fact that cocoa methylxanthines and theobromine and caffeine increased the concentration of SREMs in plasma compared with the concentration that would be reached when CFs or pure (−)-epicatechin were consumed alone may explain how cocoa methylxanthines may enhance the vascular effects of CFs. However, methylxanthines are compounds that could also interact with CF effects at a biochemical level via the modulation of biological effector processes. Methylxanthines have been reported to act on adenosine receptors and are phosphodiesterase inhibitors (26, 27). These molecular actions may also provide a feasible explanation for a synergistic effect of CFs and methylxanthines at the level of CACs, diastolic BP, FMD, and PWV. However, because the mechanisms of action of CFs have not yet not been fully elucidated, it is difficult to ascertain whether the effect of methylxanthines on adenosine receptors and phosphodiesterase activity are related to the CF-methylxanthine interactions that modulate the vascular effects observed herein or whether there are still other molecular targets yet to be identified. Thus, future studies are needed to fully understand CF-methylxanthine interactions and the potential molecular events that mediate the observed synergies on the level of vascular function.

The methylxanthines in cocoa are composed predominantly of theobromine, with only small amounts of caffeine (110 mg theobromine and 10 mg caffeine). However, dietary flavanols are also found in other food sources in which the predominant methylxanthine is caffeine, as is the case for tea, which represents the largest contributor of flavanols in the European diet (1). In this context, it is pertinent to ask whether the findings presented in this study can be extrapolated to circumstances in which flavanols are co-ingested with other types of methylxanthines, particularly caffeine. Previous studies have suggested that theobromine and caffeine may have different potencies when mediating

**FIGURE 4** Time course of endothelial function (FMD) (A) and SREMs (B) in plasma after the ingestion of CFs (green lines) alone or co-ingested with MXs (red lines). (C) Time course of SREMs in plasma after the intake of (−)-epicatechin alone (green line) or (−)-epicatechin and theobromine and caffeine (red line). Symbols are mean values and error bars are SDs. **A** ANOVA; \( P = 0.0004 \) (A), \( P = 0.0052 \) (B), and \( P = 0.004 \) (C) for time-by-treatment interactions. \(*P < 0.05\) compared with respective baseline at 0 h. \(#P < 0.05\) compared with respective CF or (−)-epicatechin administration. CF, cocoa flavanol; FMD, flow-mediated vasodilation; MX, methylxanthine; SREM, structurally related (−)-epicatechin metabolite.
a given effect (12, 28). With regard to BP, BP-lowering and BP-increasing effects have been reported for theobromine and caffeine, respectively. In healthy volunteers, the intake of 700 mg theobromine decreased BP acutely, whereas 120 mg caffeine increased BP (12). Other studies have suggested that caffeine may adversely affect arterial stiffness (14, 29), whereas the consumption of chocolate containing theobromine did not show any effect on arterial stiffness (30, 31). Thus, the extrapolation of our findings to other foods than cocoa, including green and black tea, requires further investigation. We investigated the vascular effects after the intake of CFs and methylxanthines under conditions in which these substances were either ingested together or individually and in amounts that ranged between 0 and 820 mg for CFs and 0 and 220 mg for methylxanthines. The intake amount ranges investigated in this study encompass the daily intake amounts observed in population-based assessments (1) and are thus relevant in the context of nutrition. The key findings were as follows: 1) CF-mediated vascular effects were enhanced when CFs were co-ingested with methylxanthines, whereas the ingestion of cocoa methylxanthines alone did not result in significant effects on the assessed biomarkers of vascular function; 2) the modulation of CF-related vascular effects by the co-ingestion of methylxanthines depended on the relative amount of CFs and methylxanthines consumed; and 3) the co-ingestion of CFs and methylxanthines resulted in a significantly higher SREM Cmax of CF-related vascular effects by the co-ingestion of methylxanthines. The intake amount ranges investigated in this study encompass the daily intake amounts observed in population-based assessments (1) and are thus relevant in the context of nutrition. The key findings were as follows: 1) CF-mediated vascular effects were enhanced when CFs were co-ingested with methylxanthines, whereas the ingestion of cocoa methylxanthines alone did not result in significant effects on the assessed biomarkers of vascular function; 2) the modulation of CF-related vascular effects by the co-ingestion of methylxanthines depended on the relative amount of CFs and methylxanthines consumed; and 3) the co-ingestion of CFs and methylxanthines resulted in a significantly higher SREM Cmax and AUC of the plasma concentration over time than CF intake alone. Taken together, our results demonstrate a significant interaction between cocoa methylxanthines and CFs in which methylxanthines, likely by affecting CF absorption, enhance the vascular effects commonly ascribed to CF intake with cocoa. The authors’ responsibilities were as follows—JIO, MWM, HS, and CH: designed the research; RS, JIO, AR-M, YH, and DN: conducted the research; HS: provided the test products; RS, JIO, and JPS: analyzed the data and performed the statistical analysis; JIO, AC, MK, HS, and CH: wrote the manuscript; RS, AC, and CH: had primary responsibility for the final content; and all authors: read and approved the final manuscript. JO and HS are employed by Mars Inc., a company engaged in flavanol research and flavanol-related commercial activities. JPS, AC, MK, and CH have received unrestricted research grants from Mars Inc. None of the other authors reported a conflict of interest related to the study.

REFERENCES


